Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

61. CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion

CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion 30167331 2018 11 14 2059-7029 3 5 2018 ESMO open ESMO Open CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion. e000368 10.1136/esmoopen-2018-000368 This article is the result of a round-table discussion organised by ESMO Open in Vienna in December 2017. Its purpose is to discuss the background and advances (...) in the evidence regarding cyclin-dependent kinase 4/6 inhibitors (palbociclib, ribociclib and abemaciclib) in the treatment of metastatic and early-stage breast cancer and to explore what the key open research questions are and next steps should be. Preusser Matthias M Clinical Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria. Comprehensive Cancer Centre, Medical University Vienna - General Hospital, Vienna, Austria. De Mattos-Arruda Leticia L Vall d'Hebron

ESMO open2018 Full Text: Link to full Text with Trip Pro

62. Clinical relevance of the 21-gene Recurrence Score® assay in treatment decisions for patients with node-positive breast cancer in the genomic era

Clinical relevance of the 21-gene Recurrence Score® assay in treatment decisions for patients with node-positive breast cancer in the genomic era 30155517 2018 11 14 2374-4677 4 2018 NPJ breast cancer NPJ Breast Cancer Clinical relevance of the 21-gene Recurrence Score ® assay in treatment decisions for patients with node-positive breast cancer in the genomic era. 27 10.1038/s41523-018-0082-6 In contemporary management of early-stage breast cancer, clinical decisions regarding adjuvant (...) systemic therapy are increasingly made after considering both genomic assay results and clinico-pathologic features. Genomic information augments the prognostic information gleaned from clinico-pathologic features by providing risk estimates for distant recurrence and/or breast cancer-specific survival based on individual tumor biology. The 21-gene Oncotype DX Breast Recurrence Score ® (RS) assay is validated to be prognostic and predictive of chemotherapy benefit in patients with hormone receptor

NPJ breast cancer2018 Full Text: Link to full Text with Trip Pro

63. Cognitive function following breast cancer treatment and associations with concurrent symptoms

Cognitive function following breast cancer treatment and associations with concurrent symptoms 30131974 2018 11 14 2374-4677 4 2018 NPJ breast cancer NPJ Breast Cancer Cognitive function following breast cancer treatment and associations with concurrent symptoms. 25 10.1038/s41523-018-0076-4 Cognitive changes after breast cancer treatment are often attributed to chemotherapy, without considering other important factors such as other treatments (e.g., surgery, radiation, endocrine therapy (ET (...) )). We compared neuropsychological functioning in the domains of learning, memory, attention, visuospatial, executive function, and processing speed according to primary breast cancer treatment exposures in early survivorship, before the initiation of ET ( n = 189). We were also interested in the association of neuropsychological functioning with select clinical, psychological, and behavioral factors. Compared to those who only underwent surgery ( n = 28), all neuropsychological domain scores were

NPJ breast cancer2018 Full Text: Link to full Text with Trip Pro

64. Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint

Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint 30131975 2018 11 14 2374-4677 4 2018 NPJ breast cancer NPJ Breast Cancer Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint. 26 10.1038/s41523-018-0074-6 Advances in the surgical management of the axilla in patients treated with neoadjuvant chemotherapy, especially those with node positive disease (...) Comprehensive Cancer Center, San Francisco, CA USA. 0000 0001 2297 6811 grid.266102.1 Perlmutter Jane J Patient Representative, Ann Arbor, Michigan USA. Esserman Laura J LJ 2UCSF Heller Diller Family Comprehensive Cancer Center, San Francisco, CA USA. 0000 0001 2297 6811 grid.266102.1 and I-SPY 2 Investigators eng Journal Article Review 2018 08 17 United States NPJ Breast Cancer 101674891 2374-4677 The authors declare no competing interests. Chien A Jo AJ Forero-Torres Andres A Yee Douglas D Ellis Erin D ED

NPJ breast cancer2018 Full Text: Link to full Text with Trip Pro

65. Exploration of PET and MRI radiomic features for decoding breast cancer phenotypes and prognosis

Exploration of PET and MRI radiomic features for decoding breast cancer phenotypes and prognosis 30131973 2018 11 14 2374-4677 4 2018 NPJ breast cancer NPJ Breast Cancer Exploration of PET and MRI radiomic features for decoding breast cancer phenotypes and prognosis. 24 10.1038/s41523-018-0078-2 Radiomics is an emerging technology for imaging biomarker discovery and disease-specific personalized treatment management. This paper aims to determine the benefit of using multi-modality radiomics (...) data from PET and MR images in the characterization breast cancer phenotype and prognosis. Eighty-four features were extracted from PET and MR images of 113 breast cancer patients. Unsupervised clustering based on PET and MRI radiomic features created three subgroups. These derived subgroups were statistically significantly associated with tumor grade ( p = 2.0 × 10 -6 ), tumor overall stage ( p = 0.037), breast cancer subtypes ( p = 0.0085), and disease recurrence status ( p = 0.0053). The PET

NPJ breast cancer2018 Full Text: Link to full Text with Trip Pro

66. Is there a role for immunotherapy in HER2-positive breast cancer?

Is there a role for immunotherapy in HER2-positive breast cancer? 30131972 2018 11 14 2374-4677 4 2018 NPJ breast cancer NPJ Breast Cancer Is there a role for immunotherapy in HER2-positive breast cancer? 21 10.1038/s41523-018-0072-8 Although the prognosis and prediction of therapeutic benefit for breast cancer patients overexpressing the human epidermal growth factor receptor 2 (HER2) have dramatically changed with the administration of anti-HER2-targeted therapies, HER2-positive metastatic (...) breast cancer is still an incurable disease. Thus, new and better therapeutic options are urgently needed. Among them, are the agents stemming from the field of immunology that have been the focus of impressive scientific progress and new therapeutic opportunities seem to emerge "every day" in a variety of tumor types. Holgado Esther E 1Ramon y Cajal University Hospital, Ctra, Colmenar Viejo km. 9,100, 28034 Madrid, Spain. 0000 0000 9248 5770 grid.411347.4 IOB Institute of Oncology, Quiron Group

NPJ breast cancer2018 Full Text: Link to full Text with Trip Pro

67. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. Background The poly(adenosine diphosphate-ribose) inhibitor talazoparib has shown antitumor activity in patients with advanced breast cancer and germline mutations in BRCA1 and BRCA2 ( BRCA1/2). Methods We conducted a randomized, open-label, phase 3 trial in which patients with advanced breast cancer and a germline BRCA1/2 mutation were assigned, in a 2:1 ratio, to receive talazoparib (1 mg once daily) or standard (...) % of the patients who received talazoparib and in 38% of the patients who received standard therapy; nonhematologic grade 3 adverse events occurred in 32% and 38% of the patients, respectively. Patient-reported outcomes favored talazoparib; significant overall improvements and significant delays in the time to clinically meaningful deterioration according to both the global health status-quality-of-life and breast symptoms scales were observed. Conclusions Among patients with advanced breast cancer

NEJM2018

68. Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutations

Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutations 30109263 2018 11 14 2374-4677 4 2018 NPJ breast cancer NPJ Breast Cancer Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutations. 23 10.1038/s41523-018-0077-3 Breast cancer diagnosed during pregnancy (BCP) is a rare and highly challenging disease (...) . To investigate the impact of pregnancy on the biology of breast cancer, we conducted a comparative analysis of a cohort of BCP patients and non-pregnant control patients by integrating gene expression, copy number alterations and whole genome sequencing data. We showed that BCP exhibit unique molecular characteristics including an enrichment of non-silent mutations, a higher frequency of mutations in mucin gene family and an enrichment of mismatch repair deficiency mutational signature. This provides

NPJ breast cancer2018 Full Text: Link to full Text with Trip Pro

69. MiR-221/222 promote epithelial-mesenchymal transition by targeting Notch3 in breast cancer cell lines

MiR-221/222 promote epithelial-mesenchymal transition by targeting Notch3 in breast cancer cell lines 30109262 2018 11 14 2374-4677 4 2018 NPJ breast cancer NPJ Breast Cancer MiR-221/222 promote epithelial-mesenchymal transition by targeting Notch3 in breast cancer cell lines. 20 10.1038/s41523-018-0073-7 Basal-like breast cancer (BLBC) is an aggressive subtype with a strong tendency to metastasize. Due to the lack of effective chemotherapy, BLBC has a poor prognosis compared with luminal (...) subtype breast cancer. MicroRNA-221 and -222 (miR-221/222) are overexpressed in BLBC and associate with metastasis as well as poor prognosis; however, the mechanisms by which miR-221/222 function as oncomiRs remain unknown. Here, we report that miR-221/222 expression is inversely correlated with Notch3 expression in breast cancer cell lines. Notch3 is known to be overexpressed in luminal breast cancer cells and inhibits epithelial to mesenchymal transition (EMT). We demonstrate that miR-221/222 target

NPJ breast cancer2018 Full Text: Link to full Text with Trip Pro

70. Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer

Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer 30083595 2018 11 14 2374-4677 4 2018 NPJ breast cancer NPJ Breast Cancer Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer. 22 10.1038/s41523-018-0075-5 ESR1 mutations were recently found to be an important mechanism of endocrine resistance in ER-positive (ER + ) metastatic breast cancer. To determine (...) the clinicopathological features driving the emergence of the ESR1 mutations we studied plasma cfDNA and detailed clinical data collected from patients with metastatic breast cancer. Droplet Digital PCR was performed for the detection of the most common ESR1 mutations and PIK3CA mutations. Among the patients with ER + /HER2- disease, ESR1 mutations were detected in 30% of the patients. There were no associations between the pathological features of the primary disease or time to distant recurrence and the emergence

NPJ breast cancer2018 Full Text: Link to full Text with Trip Pro

72. Adequacy of Pathologic Reports of Invasive Breast Cancer From Mastectomy Specimens at Tikur Anbessa Specialized Hospital Oncology Center in Ethiopia

Adequacy of Pathologic Reports of Invasive Breast Cancer From Mastectomy Specimens at Tikur Anbessa Specialized Hospital Oncology Center in Ethiopia 30084708 2018 12 07 2378-9506 4 2018 Jul Journal of global oncology J Glob Oncol Adequacy of Pathologic Reports of Invasive Breast Cancer From Mastectomy Specimens at Tikur Anbessa Specialized Hospital Oncology Center in Ethiopia. 1-12 10.1200/JGO.17.00198 Purpose Although information from pathology reports is essential to the care of individuals (...) with cancer and to population-level cancer control, no systematic evidence exists regarding the adequacy of breast pathology reporting in Ethiopia. This study audited pathology reports of mastectomy specimens from patients evaluated at the Tikur Anbessa Specialized Hospital Oncology Center in Addis Ababa, Ethiopia. Methods Mastectomy pathology reports from February 2014 through January 2016 were assessed for gross and microscopic information considered by the Breast Cancer Initiative 2.5 (BCI 2.5

Journal of global oncology2018 Full Text: Link to full Text with Trip Pro

73. Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer and Brain Metastases

Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer and Brain Metastases ');//--> ');//--> Search in: Menu COOKIES REQUIRED In order to access this website, please configure your browser to support cookies. ASCO Family of Sites Journals Publications Education Other Sites 2318 Mill Road, Suite 800, Alexandria, VA 22314 © 2018 American Society of Clinical Oncology |

American Society of Clinical Oncology Guidelines2018

74. Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer ');//--> ');//--> Search in: Menu COOKIES REQUIRED In order to access this website, please configure your browser to support cookies. ASCO Family of Sites Journals Publications Education Other Sites 2318 Mill Road, Suite 800, Alexandria, VA 22314 © 2018 American Society of Clinical Oncology |

American Society of Clinical Oncology Guidelines2018

75. Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data

Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data 29718793 2018 06 27 1527-7755 36 19 2018 Jul 01 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function (...) and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data. 1981-1990 10.1200/JCO.2018.78.0858 Purpose The role of temporary ovarian suppression with gonadotropin-releasing hormone agonists (GnRHa) during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal women remains controversial. This systematic review and meta-analysis using individual patient-level data was conducted to better assess

EvidenceUpdates2018

76. Should thoracic paravertebral blocks be used to prevent chronic postsurgical pain after breast cancer surgery? A systematic analysis of evidence in light of IMMPACT recommendations

Should thoracic paravertebral blocks be used to prevent chronic postsurgical pain after breast cancer surgery? A systematic analysis of evidence in light of IMMPACT recommendations 29794879 2018 06 22 1872-6623 2018 May 23 Pain Pain Should thoracic paravertebral blocks be used to prevent chronic postsurgical pain after breast cancer surgery? A systematic analysis of evidence in light of IMMPACT recommendations. 10.1097/j.pain.0000000000001292 The role of thoracic paravertebral block (PVB (...) ) in preventing chronic postsurgical pain (CPSP) after breast cancer surgery (BCS) has gained interest, but existing evidence is conflicting, and its methodological quality is unclear. This meta-analysis evaluates efficacy of PVB, compared with Control group, in preventing CPSP after BCS, in light of the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) recommendations. Electronic databases were searched for randomized trials comparing PVB with Control group for CPSP

EvidenceUpdates2018

77. Breast cancer

Breast cancer Top results for breast cancer - Trip Database or use your Google+ account Liberating the literature My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for breast cancer The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

78. Breast cancer screening

Breast cancer screening Top results for breast cancer screening - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers (...) in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for breast cancer screening The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection

Trip Latest and Greatest2018

79. Gene expression profiling to guide selection of adjuvant therapy in breast cancer

Gene expression profiling to guide selection of adjuvant therapy in breast cancer Gene expression profiling to guide selection of adjuvant therapy in breast cancer We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Gene expression profiling to guide selection of adjuvant therapy in breast cancer Share: Reading time approx. 6 minutes Breast cancer (...) on a research basis. Question What is the current state of scientific knowledge regarding gene expression profiling to guide selection of adjuvant therapy in breast cancer? Identified literature Wang SY, Dang W, Richman I, Mougalian SS, Evans SB, Gross CP. Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal. J Clin Oncol 2018:Jco2017765941. Blok EJ, Bastiaannet E, van den Hout WB, Liefers GJ, Smit V, Kroep JR, et al. Systematic review of the clinical

Swedish Council on Technology Assessement2018

80. Effectiveness of Botulinum Toxin A for Persistent Upper Limb Pain After Breast Cancer Treatment: A Double-Blinded Randomized Controlled Trial

Effectiveness of Botulinum Toxin A for Persistent Upper Limb Pain After Breast Cancer Treatment: A Double-Blinded Randomized Controlled Trial 29409922 2018 06 25 1532-821X 99 7 2018 Jul Archives of physical medicine and rehabilitation Arch Phys Med Rehabil Effectiveness of Botulinum Toxin A for Persistent Upper Limb Pain After Breast Cancer Treatment: A Double-Blinded Randomized Controlled Trial. 1342-1351 S0003-9993(18)30067-4 10.1016/j.apmr.2017.12.032 To investigate the effect of a single (...) botulinum toxin A (BTX-A) infiltration in the pectoralis major muscle in addition to a standard physical therapy program for treatment of persistent upper limb pain in breast cancer survivors. Double-blinded (patient and assessor) randomized controlled trial. A university hospital. Breast cancer patients (N=50) with pain. The intervention group received a single BTX-A infiltration. The control group received a placebo (saline) infiltration. Within 1 week after the infiltration, all patients attended

EvidenceUpdates2018